Many exciting studies about surgical management of renal cell carcinoma (RCC) were presented at Amsterdam’s 37th Annual European association of urology (EAU) congress. These studies may provide new strategies for effectively managing RCCs.
One of the presented studies by Vitruk e.a. was a retrospective analysis comparing cytoreductive partial nephrectomy (PN) versus cytoreductive radical nephrectomy (RN). The study included 109 patients (55 and 54 undergoing PN and RN) with renal parenchymal volume more significant than 50%. Patients undergoing PN had significantly longer 5-year survival compared to the RN group (32.1 vs 15.5 months). Additionally, patients in the PN group experienced a 38% decreased risk of death.
Another retrospective single-centre study by Rodler e.a. analysed the safety of robotic radiosurgery and its effectiveness for treating aged lung metastases. The study included 50 patients (49 with clear cell and 1 with papillary RCC) with a median age of 64. Among 50 patients, 64% had oligometastatic disease, and 21% received systemic therapy during RRS. Median overall survival (OS) and progression-free survival (PFS) were 35 and 13 months, respectively. Only six patients experienced adverse events (grade 1 or 2). These findings demonstrate the safety and efficacy of this surgical procedure for RCC.
The third study by Roussel e.a. characterised perioperative morbidities associated with surgical metastasectomy by examining 30-day complications after the procedure. The study enrolled 522 patients undergoing surgical metstasectomies. This procedure’s 30-day complication rate was very low (8.4%) compared to high-grade postoperative morbidity (25%), as reflected in the population registry data.
References
Rodler S, Schott M, Casuscelli J, et al. Robotic radiosurgery for the treatment of lung metastases of renal cell carcinoma. Presented at: EAU 2022, July 1-4, 2022, Amsterdam, The Netherlands. Abstract A0376.
Roussel E, Lyon TD, Sharma V, et al. Perioperative morbidity of surgical metastasectomy for renal cell carcinoma: An international multicenter study. Presented at: EAU 2022, July 1-4, 2022, Amsterdam, The Netherlands. Abstract A0373.
Top
